The pipeline for the treatment of wet age-related macular degeneration includes therapies that focus on new molecular targets. Carl J. Danzig, MD, FASRS, discusses a tyrosine kinase inhibitor.
Adapting to Progress: Vorolanib Intravitreal Implant
Media formats available:
Details
Presenters
Target Audience
This certified continuing education (CME) activity is designed for ophthalmologists involved in the management of patients with nAMD.
Grantor Statement
This activity is supported by an independent medical education grant from Ocular Therapeutix.
Learning Objectives
Upon completion of this activity, the participant should be able to:
- Summarize investigational therapies for nAMD that are in late phase clinical development
Accreditation
Provided by Evolve Medical Education
Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Evolve designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Participation Method
In order to obtain credit, proceed through the program, complete the posttest, evaluation and submit for credit.
Faculty and Disclosures
Carl J. Danzig, MD, FASRS
Director of Vitreoretinal Services
Rand Eye Institute
Assistant Affiliate Professor
Florida Atlantic University
Deerfield Beach, FLDisclosure of Conflicts of Interest
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.The following faculty/staff members have the following financial relationships with ineligible companies.
Carl J. Danzig, MD, FASRS, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: 4DMT, AbbVie, Adverum Biotechnologies, Alimera Sciences, EyeBio, Galimedix Therapeutics, Genentech, Iveric Bio/Astellas, Kodiak Sciences, Novartis, Ocular Therapeutix, Oculis, Ocuphire Pharma, Opthea, Regeneron, Regenxbio, Roche, Samsung Bioepsis, and Stealth BioTherapeutics. Grant/Research Support: 4DMT, Adverum Biotechnologies, Alexion, Annexon Biosciences, Aviceda, Bayer, Cognition, Curacle, EyeBio, Genentech, Gyroscope Therapeutics, Iveric Bio/Astellas, Kodiak Sciences, Novartis, Ocular Therapeutix, Oculis, Regeneron, Regenxbio, Rezolute, Roche, and Unity Biotechnology. Speaker's Bureau: Genentech and Iveric Bio/Astellas.
The Evolve staff, planners, and peer reviewer have no financial relationships with ineligible companies.
Disclaimer
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Ocular Therapeutix.This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
Luis A. Gonzalez, MD, MPH
Jeremiah Brown Jr., MD, MS, FASRS
Sarah H. Van Tassel, MD
Justin Schweitzer, OD, FAAO
Paul Petrakos, DO, MS
I. Paul Singh, MD
I. Paul Singh, MD
Paul Petrakos, DO, MS
